These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 39104323)

  • 1. Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease.
    Kjeldsen SAS; Werge MP; Grandt J; Richter MM; Thing M; Hetland LE; Rashu EB; Jensen AH; Winther-Sørensen M; Kellemann JS; Holst JJ; Junker AE; Serizawa RR; Vyberg M; Gluud LL; Wewer Albrechtsen NJ
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G558-G570. PubMed ID: 39104323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.
    Wewer Albrechtsen NJ; Junker AE; Christensen M; Hædersdal S; Wibrand F; Lund AM; Galsgaard KD; Holst JJ; Knop FK; Vilsbøll T
    Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G91-G96. PubMed ID: 28971838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon Resistance in Individuals With Obesity and Hepatic Steatosis Can Be Measured Using the GLUSENTIC Test and Index.
    Kjeldsen SAS; Richter MM; Jensen NJ; Nilsson MSD; Heinz N; Nybing JD; Linden FH; Høgh-Schmidt E; Boesen MP; Andersen TL; Johannesen HH; Trammell SAJ; Grevengoed TJ; Madsbad S; Vilstrup H; Schiødt FV; Møller A; Rashu EB; Nørgaard K; Schmidt S; Gluud LL; Haugaard SB; Holst JJ; Rungby J; Wewer Albrechtsen NJ
    Diabetes; 2024 Oct; 73(10):1716-1727. PubMed ID: 38976454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Liver-α-Cell Axis and Type 2 Diabetes.
    Wewer Albrechtsen NJ; Pedersen J; Galsgaard KD; Winther-Sørensen M; Suppli MP; Janah L; Gromada J; Vilstrup H; Knop FK; Holst JJ
    Endocr Rev; 2019 Oct; 40(5):1353-1366. PubMed ID: 30920583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.
    Akhverdyan N; Wieland A; Sullivan S; Lindsay M; Swartwood S; Arndt G; Kaizer LK; Jensen T
    Metab Syndr Relat Disord; 2024 Oct; 22(8):608-618. PubMed ID: 38868900
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis.
    Suppli MP; Bagger JI; Lund A; Demant M; van Hall G; Strandberg C; Kønig MJ; Rigbolt K; Langhoff JL; Wewer Albrechtsen NJ; Holst JJ; Vilsbøll T; Knop FK
    Diabetes; 2020 Jun; 69(6):1090-1099. PubMed ID: 31974144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis.
    Winther-Sørensen M; Galsgaard KD; Santos A; Trammell SAJ; Sulek K; Kuhre RE; Pedersen J; Andersen DB; Hassing AS; Dall M; Treebak JT; Gillum MP; Torekov SS; Windeløv JA; Hunt JE; Kjeldsen SAS; Jepsen SL; Vasilopoulou CG; Knop FK; Ørskov C; Werge MP; Bisgaard HC; Eriksen PL; Vilstrup H; Gluud LL; Holst JJ; Wewer Albrechtsen NJ
    Mol Metab; 2020 Dec; 42():101080. PubMed ID: 32937194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable glucagon-stimulated amino acid suppression in individuals with and without hepatic steatosis or steatohepatitis.
    Heebøll S; Wegener G; Grønbæk H; Nielsen S
    Am J Physiol Endocrinol Metab; 2024 Sep; ():. PubMed ID: 39291967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study.
    Winther-Sørensen M; Garcia SL; Bartholdy A; Ottenheijm ME; Banasik K; Brunak S; Sørensen CM; Gluud LL; Knop FK; Holst JJ; Rosenkilde MM; Jensen MK; Wewer Albrechtsen NJ
    Diabetologia; 2024 Aug; 67(8):1602-1615. PubMed ID: 38705923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects.
    Demant M; Bagger JI; Suppli MP; Lund A; Gyldenløve M; Hansen KB; Hare KJ; Christensen M; Sonne DP; Holst JJ; Vilsbøll T; Knop FK
    Metab Syndr Relat Disord; 2018 Dec; 16(10):530-536. PubMed ID: 30325692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Scavo MP; Lisco G; Depalo N; Rizzi F; Volpe S; Arrè V; Carrieri L; Notarnicola M; De Nunzio V; Curri ML; De Pergola G; Piazzolla G; Giannelli G
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen.
    Sharma A; Godina Leiva E; Kalavalapalli S; Lomonaco R; Marangi SA; Valdez Saenz E; Gonzalez MA; Ortiz Rocha A; Cuervo Pardo N; Rosenberg J; Bedossa P; Bril F; Barb D; Cusi K
    Obesity (Silver Spring); 2024 Oct; 32(10):1967-1974. PubMed ID: 39315409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight-adjusted waist index is positively and linearly associated with all-cause and cardiovascular mortality in metabolic dysfunction-associated steatotic liver disease: findings from NHANES 1999-2018.
    Liu W; Yang X; Zhan T; Huang M; Tian X; Tian X; Huang X
    Front Endocrinol (Lausanne); 2024; 15():1457869. PubMed ID: 39403588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes.
    Al-Ozairi E; Irshad M; AlKandari J; Mashankar A; Alroudhan D; le Roux CW
    Diabetes Obes Metab; 2024 Sep; 26(9):4052-4059. PubMed ID: 38984381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
    Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence.
    McGlone ER; Bloom SR; Tan TM
    J Endocrinol; 2024 Jun; 261(3):. PubMed ID: 38579751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Dysfunction-Associated Steatotic Liver Disease in Severe Obesity and Concordance between Invasive (Biopsy) and Noninvasive (OWLiver®) Diagnoses.
    Navarro-Masip È; Mestres Petit N; Salinas-Roca B; Herrerías F; Vilardell F; de la Fuente MC; Pallares J; Santamaría M; Zorzano-Martínez M; Sánchez E; Matías-Guiu X; López-Cano C; Soler AG; León-Mengíbar J; Bueno M; Lecube A
    Obes Facts; 2024; 17(5):473-482. PubMed ID: 38934179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.